Shiseido Co., Ltd. announced plans to open its Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize the company's R&D efforts in hair regenerative medicine, with an aim toward commercialization. With the goal of clinically applying regenerative medicine to treat alopecia and thinning hair, Shiseido established a technical collaboration agreement in July 2013 with Canadian bio-venture company RepliCel Life Sciences, Inc., by acquiring an exclusive geographic license to use its RepliCel Hair-01 (RCH-01) hair regeneration technology in Asia.
RCH-01 has been developed over 10 years, and safe application in humans has been validated by RepliCel’s phase 1 clinical trial. RepliCel has patents issued for hair follicle mesenchymal stem cells and their use in Japan, the United States, Australia and the European Union. According to the company, RCH-01 is an “autologous cell transplantation technology,” in which specific cells isolated from the hair follicles taken from the scalp of a patient are cultured and implanted (injected) into the balding scalp area, potentially stimulating residing hair follicles and promoting new growth in the balding scalp area.
This content is adapted from an article in GCI Magazine. The original version can be found here.